Modality
ADC
MOA
KRASG12Ci
Target
C5
Pathway
Hedgehog
CLLCrohn's
Development Pipeline
Preclinical
Jul 2017
→ Nov 2030
PreclinicalCurrent
NCT04469275
2,627 pts·Crohn's
2023-12→2030-11·Terminated
NCT06716051
1,562 pts·CLL
2017-07→2025-07·Active
4,189 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-07-029mo agoInterim· CLL
2030-11-254.7y awayInterim· Crohn's
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Preclinical
Active
Preclinical
Termina…
Catalysts
Interim
2025-07-02 · 9mo ago
CLL
Interim
2030-11-25 · 4.7y away
Crohn's
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04469275 | Preclinical | Crohn's | Terminated | 2627 | MRD |
| NCT06716051 | Preclinical | CLL | Active | 1562 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| ALN-6288 | Alnylam | Approved | LAG-3 |